News|Videos|January 29, 2025

Sustainability in Pharmaceutical Outsourcing

Author(s)Susan Haigney

Pharmaceutical Technology® spoke with Saharsh Davuluri, Vice-Chairman and Managing Director, Neuland Laboratories, to see how the push to sustainability is impacting contract manufacturers.

The pharmaceutical industry has a significant impact on the environment that includes CO2 emissions, water consumption, use of plastics, and a variety of manufacturing practices (1). Therefore, sustainability and green manufacturing are becoming priorities for the pharmaceutical industry due to evolving and changing regulations to protect both the environment and patients.

Pharmaceutical Technology® spoke with Saharsh Davuluri, Vice-Chairman and Managing Director, Neuland Laboratories, to see how the push to sustainability is impacting contract manufacturers as they work with sponsors on the development and manufacture of drugs and biologics in a sustainable fashion that aligns with industry and regulatory requirements.

“Sponsors are increasingly requiring sustainable or green manufacturing practices when negotiating for partnerships with Neuland,” says Davuluri. “I think this trend is also kind of aligned with the broader industry shift towards sustainability … we are seeing that a lot of these companies are having their own approach on or their own frameworks in what they would like to measure their partners with. This is not just about Europe versus US, but also within a particular geography, every company has a different approach. Earlier, we used to see only big pharma or large generic companies having particular requirements. But now we're even seeing a lot of small to mid-sized biotechs talking to us and measuring us on our sustainability related practices as well.”

Click the video above to watch the interview.

Reference

1. Di Russo, M.; Zjalic, D.; Lombardi, G.S.; Perilli, A.; Congedo, G.; Daugbjerg, S.; Cadeddu, C. Impact of the 50 Biggest Pharma Companies: A Review of Environmental Report Aspiring to NetZero. European Journal of Public Health2023, 33, Issue Supplement_2 https://doi.org/10.1093/eurpub/ckad160.1182

About the speaker

Saharsh Davuluri is Vice-Chairman and Managing Director, Neuland Laboratories. Saharsh is an electrical engineering graduate and obtained his master’s in management information systems from Weatherhead School of Management, Cleveland, Ohio, USA. He also secured Master of Business Administration from University of North Carolina, USA. He has worked in the past with Sify Limited in various roles in the Sales organization. He joined Neuland in 2007, with responsibility for initiating the Custom Manufacturing Solutions (CMS) business. He is currently responsible for all marketing, information technology (IT), and business development activities along with oversight of R&D.


Related to this article

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.